Effect of interferon α‐2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis

Kurokawa, Mikio; Hiramatsu, Naoki; Oze, Tsugiko; Mochizuki, Kiyoshi; Yakushijin, Takayuki; Kurashige, Nao; Inoue, Yuko; Igura, Takumi; Imanaka, Kazuho; Yamada, Akira; Oshita, Masahide; Hagiwara, Hideki; Mita, Eiji; Ito, Toshifumi; Inui, Yoshiaki; Hijioka, Taizo; Yoshihara, Hiroyuki; Imai, Yumiko; Kato, Masaaki; Kiso, Shinichi; Kanto, Tatsuya; Takehara, Tetsuo; Kasahara, Akinori; Hayashi, Norio

doi:10.1111/j.1872-034x.2008.00477.x

Cited by 29 publications

(41 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results suggest that IFN therapy inhibits the development of HCC in comparison with untreated patients, and that not only SVR but also BR are related to the prevention of HCC. Furthermore, a retrospective cohort study regarding the inhibitory effects of combination therapy with IFN and ribavirin on HCC in patients with chronic hepatitis C showed that the risk of HCC development was significantly lower in responders to this combination therapy [19]. Based on these findings, it is recommended that antiviral therapy with IFN be performed to prevent HCC incidence in patients with chronic hepatitis C. The primary goal of IFN treatment is virus eradication (SVR).…”

Section: Preventionmentioning

confidence: 99%

Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version

Kudo

Izumi

Kokudo

et al. 2011

Dig Dis

712

634

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death not only in Japan but also worldwide. Clinical practice guidelines for HCC were first published in 2001 by the European Society of Study of the Liver (EASL) followed by the American Association for the Study of Liver Disease (AASLD) published in 2005 and updated in 2010. However, these guidelines have proven to be somewhat unsuitable for Japanese patients. In 2005, supported by the Japanese Ministry of Health, Labour and Welfare, evidence-based clinical practice guidelines for HCC were compiled in Japan. In 2009, a revised version of evidence-based guidelines was published. Based on both ‘evidence-based’ guidelines and the consensus of an expert panel on HCC, the Japan Society of Hepatology (JSH) published the Consensus-Based Clinical Practice Manual in 2007 and updated in 2010. In this article, the 2010 updated version of this manual, especially issues on prevention, surveillance, pathology, diagnosis, staging, and treatment algorithm are summarized.

show abstract

Section: Preventionmentioning

confidence: 99%

Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version

Kudo

Izumi

Kokudo

et al. 2011

Dig Dis

712

634

View full text Add to dashboard Cite

show abstract

“…As a result, the absolute reduction in risk was 4.6% (CI, 4.2% to 5.0%) for patients achieving an SVR. All of the studies included in the meta-analysis adjusted for age, 9 studies controlled for fibrosis stage (17,27,36,50,51,53,57,58,61), and some studies (46,54) controlled for fibrosis stage with typical markers for advanced fibrosis. One study did not exclude patients with positive hepatitis B serologic test results, but its model was adjusted for the presence of hepatitis B (27).…”

Section: Hcc Development After Treatment Of Hepatitis C In Persons Atmentioning

confidence: 99%

Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma

Morgan

Baack²,

Smith³

et al. 2013

Ann Intern Med

779

628

View full text Add to dashboard Cite

“…Also, the recent introduction of direct-acting antiviral agents such as boceprevir and telaprevir has been shown to improve sustained virological response (SVR) by up to 63-75% in treatment-naïve HCV genotype 1 patients [8]. Achievement of SVR after treatment has been associated with improvement in disease progression and liver histology, as well as a reduced risk of HCC and liver-related mortality [9,10,11,12,13]. …”

Section: Introductionmentioning

confidence: 99%

Long-Term Follow-Up of Chronic Hepatitis C Patients Treated with Interferon-Alpha: Risk of Cirrhosis and Hepatocellular Carcinoma in a Single Center over 10 Years

Lee

Yeon²,

Yoon³

et al. 2015

Intervirology

View full text Add to dashboard Cite

Objectives: Interferon (IFN)-based therapy for chronic hepatitis C (CHC) is cost-effective and is associated with reduced risk of disease progression. We aimed to assess the incidence of cirrhosis and hepatocellular carcinoma (HCC) and to identify risk factors associated with disease progression. Methods: We retrospectively reviewed 280 CHC patients who were registered at our hospital between 2001 and 2010. Results: About 80% of patients received antiviral treatment. The 10-year cumulative incidence of cirrhosis was significantly lower among patients who received antiviral therapy than among those who did not (8.3 vs. 44.0%; p = 0.001). Among them, patients with sustained virological response (SVR) had a significantly lower incidence of cirrhosis than those without SVR (0.6 vs. 33.9%; p < 0.001). Cox proportional hazards regression showed that SVR was the significant independent factor for reducing the risk of cirrhosis (hazard ratio, HR = 0.03; p = 0.034). The 10-year cumulative incidence of HCC was higher among patients who did not receive antiviral therapy than among those who did (43.9 vs. 6.1%; p < 0.001). Multivariate analysis showed that underlying cirrhosis was the only independent risk factor associated with HCC development (HR = 7.70; p = 0.010). Conclusions: SVR secondary to IFN-based therapy could reduce cirrhosis development in CHC patients. Underlying cirrhosis was the strongest predictor of HCC development.

show abstract

Effect of interferon α‐2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis

Abstract: These results suggest that the attainment of SVR or continuous normalization of ALT levels after IFN therapy can affect patients apart from HCC development.

Cited by 29 publications

References 29 publications

Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version

Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version

Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma

Long-Term Follow-Up of Chronic Hepatitis C Patients Treated with Interferon-Alpha: Risk of Cirrhosis and Hepatocellular Carcinoma in a Single Center over 10 Years

Contact Info

Product

Resources

About